Today: 10 June 2026
Browse Category

NASDAQ:GRRR 18 November 2025 - 7 December 2025

Gorilla Technology (GRRR) Stock on December 7, 2025: Latest News, CVR Shake-Up, Forecasts and Analyst Outlook

Gorilla Technology (GRRR) Stock on December 7, 2025: Latest News, CVR Shake-Up, Forecasts and Analyst Outlook

Gorilla Technology (NASDAQ: GRRR) closed at $14.97 on December 5, down 3.36%, with after-hours trading at $15.03 and a market cap near $430 million. Q3 revenue reached a record $26.5 million, up 32% year-on-year. The company reported a $1.4 billion AI data-center mandate and a $7 billion pipeline. Analyst price targets vary widely, from $18 to $39.
7 December 2025
·
Gorilla Technology Group (GRRR) Stock: CVR Payout, Nobel Sustainability Nomination and a $1.4 Billion AI Bet – What Investors Need to Know Now

Gorilla Technology Group (GRRR) Stock: CVR Payout, Nobel Sustainability Nomination and a $1.4 Billion AI Bet – What Investors Need to Know Now

Gorilla Technology (NASDAQ: GRRR) closed at $14.97 on Dec. 5, 2025, with a market cap near $350–430 million and short interest at 12%. The company secured a $1.4 billion AI data-center contract in Southeast Asia and reported record revenue, but posted a $67 million net loss over the past year. GRRR shares are up over 150% in 12 months but down 20–25% in the past six months. Analyst opinions remain sharply split.
6 December 2025
·
Gorilla Technology (GRRR) Soars on Record Q3 Earnings, $1.4B AI Data Centre Deal and Bullish 2026 Outlook

Gorilla Technology (GRRR) Soars on Record Q3 Earnings, $1.4B AI Data Centre Deal and Bullish 2026 Outlook

Gorilla Technology Group shares surged November 18 after the company reported record Q3 2025 results, including $26.5 million in revenue, a swing to positive operating income, and near-breakeven net loss. The company confirmed a $1.4 billion AI data centre mandate in Southeast Asia and reported cash of $121.4 million with debt down to $15.1 million.
18 November 2025
····

Stock Market Today

  • SenSen Networks Limited (ASX:SNS) Shows Potential Undervaluation Amid Positive Earnings Outlook
    June 10, 2026, 5:44 PM EDT. SenSen Networks Limited (ASX:SNS) has experienced a 10% share price increase recently yet still trades below its yearly highs. The company's price-to-earnings (PE) ratio stands at 13.31x, significantly below the software industry average of 25.62x, suggesting potential undervaluation. SenSen's high beta indicates notable price volatility, providing additional buying opportunities. The firm's earnings growth is projected in the teens over the coming years, signaling robust future cash flows and a promising outlook. Investors may find value in accumulating more shares as the market may not fully price in this growth. However, considerations around the company's financial health remain crucial before investment decisions.

Latest articles

YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Snap Inc. Targets Health Ad Dollars With New Snapchat Study as Pressure Builds

Snap Shares Drop Again With Tech Names Under Pressure

10 June 2026
Snap Inc. shares slid 4% to $5.38, extending a three-day losing streak and deepening doubts about its turnaround despite improved cash flow and cost cuts, as investors await CEO Evan Spiegel’s June 16 AWE keynote and weigh weak ad growth, falling eCPMs, and ongoing macro and regulatory risks.
Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

10 June 2026
Outlook Therapeutics soared 26% to $0.89 on heavy volume as investors zeroed in on the FDA’s 60-day review window for Lytenava after a successful appeal, but risks remain with the stock still under $1, looming Nasdaq compliance deadlines, and warnings of possible dilution and going-concern doubts if FDA approval or favorable labeling isn’t secured soon.
Go toTop